MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2022-002265

Медицинская библиотека · RMD open · 2022

Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.

Verstappen Gwenny M, de Wolff Liseth, Arends Suzanne, Heiermann Hella-Marie, van Sleen Yannick, Visser Annie, Terpstra Janneke H, Diavatopoulos Dimitri A, van der Heiden Marieke, Vissink Arjan, van Baarle Debbie, Kroese Frans G M, Bootsma Hendrika

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

To evaluate humoral and cellular immune responses and adverse events (AEs) after COVID-19 vaccination in patients with primary Sjögren's syndrome (pSS) compared to healthy controls (HC), and disease activity following vaccination in patients with pSS.

METHODS

67 patients with pSS and 33 HC (ratio 2:1) received COVID-19 vaccinations following the Dutch vaccination programme. Patients with pSS did not use immunomodulatory drugs, except hydroxychloroquine. Anti-spike 1 receptor binding domain IgG serum antibody levels were measured 28 days after complete vaccination. AEs were collected 7 days after vaccination. In a subgroup, salivary anti-SARS-CoV-2 antibodies and T-cell response by interferon-γ enzyme-linked immune absorbent spot was measured.

RESULTS

47 patients with pSS (70%) and 14 HC (42%) received BNT162b2 (Pfizer-BioNtech), 13 (19%) and 5 (15%) received ChAdOx1 nCoV-19 (AstraZeneca), 6 (9%) and 8 (24%) received mRNA-1273 (Moderna), and 1 (1%) and 6 (18%) received Ad.26.COV2.S (Janssen). All participants had positive anti-SARS-CoV-2 antibody levels (>2500 AU/mL) postvaccination. No differences in anti-SARS-CoV-2 antibody levels were observed between patients with pSS and HC, for each vaccine type. Salivary anti-SARS-CoV-2 IgG antibodies also increased, and a T-cell response was observed in patients with pSS and HC. Frequencies of systemic AEs were comparable between patients with pSS and HC (first vaccination: 34/67 (51%) vs 16/33 (48%), p=0.83; second: 41/66 (62%) vs 14/25 (56%), p=0.59). No significant worsening was observed in patient-reported and systemic disease activity, including auto-antibodies.

CONCLUSIONS

Patients with pSS had similar humoral and cellular immune responses as HC, suggesting COVID-19 vaccination is effective in patients with pSS. AEs were also comparable, and no increase in disease activity was seen in patients with pSS.

Для цитирования: Verstappen Gwenny M, de Wolff Liseth, Arends Suzanne, Heiermann Hella-Marie, van Sleen Yannick, Visser Annie, Terpstra Janneke H, Diavatopoulos Dimitri A, van der Heiden Marieke, Vissink Arjan, van Baarle Debbie, Kroese Frans G M, Bootsma Hendrika. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.. RMD open. 2022. DOI: 10.1136/rmdopen-2022-002265.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.